Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
Article ID | PMID | Source | Title | Publish Year | |
---|---|---|---|---|---|
A26711 | 19915460 | Curr Opin Lipidol | Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. | 2010 | Details |
A26756 | 19799688 | J Gastroenterol Hepatol | The liver and the waistline: Fifty years of growth. | 2009 | Details |
A26777 | 19809782 | J Hepatobiliary Pancreat Sci | Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system. | 2009 | Details |
A26780 | 19798581 | Rev Endocr Metab Disord | Role of biological rhythms in gastrointestinal health and disease. | 2009 | Details |
A26812 | 19733470 | J Nutr Biochem | Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. | 2009 | Details |
A26822 | 19713474 | Am J Physiol Gastrointest Liver Physiol | Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. | 2009 | Details |
A26838 | 19679262 | J Nutr Biochem | Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. | 2009 | Details |
A26859 | 19637282 | Hepatology | Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. | 2009 | Details |
A27037 | 19291785 | Hepatology | Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. | 2009 | Details |
A27217 | 18956297 | Semin Liver Dis | Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. | 2008 | Details |
A27285 | 18752564 | J Gastroenterol Hepatol | Animal models of NASH: getting both pathology and metabolic context right. | 2008 | Details |
A27325 | 18641190 | J Nutr | Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. | 2008 | Details |
A27364 | 18537660 | Curr Pharm Des | Genomics can advance the potential for probiotic cultures to improve liver and overall health. | 2008 | Details |
A27380 | 18506935 | World J Gastroenterol | Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats. | 2008 | Details |
A27395 | 18484349 | Ann Med | Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. | 2008 | Details |
A27427 | 18336670 | J Gastroenterol Hepatol | Dysregulation of systemic iron metabolism in alcoholic liver diseases. | 2008 | Details |
A27433 | 18395289 | J Hepatol | Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. | 2008 | Details |
A27470 | 18329014 | Eur J Pharmacol | Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. | 2008 | Details |
A27480 | 18311774 | Hepatology | Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. | 2008 | Details |
A27492 | 18286348 | Obes Surg | High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. | 2008 | Details |
A27519 | 18203899 | J Nutr | Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. | 2008 | Details |
A27522 | 18198478 | J Toxicol Sci | Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. | 2007 | Details |
A27541 | 18098321 | Hepatology | Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. | 2008 | Details |
A27543 | 18095746 | Drug Saf | Orlistat-associated adverse effects and drug interactions: a critical review. | 2008 | Details |
A27781 | 17464986 | Hepatology | Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? | 2007 | Details |
A27857 | 17236122 | Z Gastroenterol | Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. | 2007 | Details |
A27858 | 17236119 | Z Gastroenterol | Lipid metabolism in the liver. | 2007 | Details |
A27960 | 16895997 | Proc Natl Acad Sci U S A | Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. | 2006 | Details |
A28027 | 16689200 | J Chin Med Assoc | Nonalcoholic fatty liver disease manifesting esophageal variceal bleeding. | 2006 | Details |
A28063 | 16540765 | J Clin Gastroenterol | Diagnostic evaluation of nonalcoholic fatty liver disease. | 2006 | Details |
A28123 | 16366738 | Altern Med Rev | Adverse effects of dietary fructose. | 2005 | Details |
A28151 | 16255293 | Rev Prat | [Epidemiology and natural history of cirrhosis]. | 2005 | Details |
A28181 | 16225467 | Aliment Pharmacol Ther | Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. | 2005 | Details |
A28210 | 16124065 | World J Gastroenterol | Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. | 2005 | Details |
A28241 | 15986870 | Dig Dis Sci | Increased orocecal transit time in patients with nonalcoholic fatty liver disease. | 2005 | Details |
A28256 | 15942443 | J Clin Gastroenterol | Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | 2005 | Details |
A28276 | 15828235 | Nihon Rinsho | [The roles of PPARs in digestive diseases]. | 2005 | Details |
A28356 | 15506670 | Dig Liver Dis | Hodgkin' s disease with fulminant non-alcoholic steatohepatitis. | 2004 | Details |
A28406 | 15191202 | Dig Liver Dis | Searching for coeliac disease in patients with non-alcoholic fatty liver disease. | 2004 | Details |
A28489 | 12643175 | Curr Diab Rep | Hepatic steatosis and type 2 diabetes mellitus. | 2002 | Details |
A28494 | 12540784 | Hepatology | Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. | 2003 | Details |
A28497 | 12516196 | Clin Liver Dis | The liver in obesity and type 2 diabetes mellitus. | 2002 | Details |
A28537 | 11907349 | J Clin Gastroenterol | Intestinal permeation and gastrointestinal disease. | 2002 | Details |
A28638 | 35211093 | Front Endocrinol (Lausanne) | The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis. | 2022 | Details |
A28806 | 34974327 | Diabetes Metab Syndr | Prevalence of metabolic syndrome in cirrhotics with gastric antral vascular ectasia. | 2021 | Details |
A29073 | 34620902 | Sci Rep | Hepatobiliary phenotype of individuals with chronic intestinal disorders. | 2021 | Details |
A29074 | 34619076 | Cell Metab | "Sweet death": Fructose as a metabolic toxin that targets the gut-liver axis. | 2021 | Details |
A29086 | 34603061 | Front Pharmacol | Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. | 2021 | Details |
A29173 | 34473374 | FASEB J | Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. | 2021 | Details |
A29341 | 34231046 | J Gastroenterol | Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. | 2021 | Details |
A29342 | 34228859 | Hepatol Res | Evidence-based clinical practice guidelines for liver cirrhosis 2020. | 2021 | Details |
A29441 | 34062281 | Cell Mol Gastroenterol Hepatol | Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. | 2021 | Details |
A29509 | 33965587 | Cell Mol Gastroenterol Hepatol | Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis. | 2021 | Details |
A29536 | 33928008 | In Silico Pharmacol | Comparative performance of extreme learning machine and Hammerstein-Weiner models for modelling the intestinal hyper-motility and secretory inhibitory effects of methanolic leaf extract of Combretumhypopilinum Diels (Combretaceae). | 2021 | Details |
A29555 | 33891996 | Cancer Lett | Examining the gut-liver axis in liver cancer using organoid models. | 2021 | Details |
A29742 | 33590776 | Gut Microbes | The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases. | 2022 | Details |
A29923 | 33268008 | Bioorg Chem | Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. | 2020 | Details |
A30256 | 32733451 | Front Immunol | The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. | 2020 | Details |
A30360 | 32575352 | Microorganisms | Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. | 2020 | Details |
A30407 | 32493884 | Exp Anim | Gender difference in development of steatohepatitis in p62/Sqstm1 and Nrf2 double-knockout mice. | 2020 | Details |
A30432 | 32453061 | Am J Gastroenterol | Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg. | 2020 | Details |
A30441 | 32441510 | ACS Nano | Targeted Delivery of Notch Inhibitor Attenuates Obesity-Induced Glucose Intolerance and Liver Fibrosis. | 2020 | Details |
A30550 | 32247663 | Pharmacol Ther | Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside. | 2020 | Details |
A30569 | 32196084 | Mil Med | Health Characteristics of the Madeira Riverine Population. | 2020 | Details |
A30722 | 31909359 | Hepatol Commun | Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model. | 2019 | Details |
A30723 | 31909358 | Hepatol Commun | Ablation of Hmgb1 in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice. | 2019 | Details |
A30937 | 31522313 | Int J Clin Oncol | The evolution of surgical treatment for gastrointestinal cancers. | 2019 | Details |
A31135 | 31183452 | BJS Open | National prospective cohort study of the burden of acute small bowel obstruction. | 2019 | Details |
A31144 | 31177586 | Hepatol Res | Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. | 2019 | Details |
A31416 | 30618372 | Ugeskr Laeger | [The gut microbiome is important in chronic liver disease]. | 2019 | Details |
A31615 | 32704804 | Transl Anim Sci | Effects of two equine digestive aid supplements on hindgut health. | 2018 | Details |
A31619 | 30186272 | Front Microbiol | Butyrate Protects Mice Against Methionine-Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels. | 2018 | Details |
A31722 | 29983886 | Oncotarget | Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. | 2018 | Details |
A31765 | 29900399 | Data Brief | The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment. | 2018 | Details |
A31766 | 29899851 | Oncotarget | Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats. | 2018 | Details |
A31826 | 29743797 | J Clin Exp Hepatol | Natural History of Cirrhosis of Liver after First Decompensation: A Prospective Study in India. | 2017 | Details |
A31833 | 29739616 | Pathology | Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. | 2018 | Details |
A31886 | 29619418 | Hepatol Commun | The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. | 2018 | Details |
A31978 | 29404501 | Hepatol Commun | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. | 2017 | Details |
A32208 | 31966360 | Int J Clin Exp Pathol | Glycine protects against non-alcoholic hepatitis by downregulation of the TLR4 signaling pathway. | 2017 | Details |
A32261 | 28831287 | Evid Based Complement Alternat Med | Extracts of Salvia-Nelumbinis Naturalis Ameliorate Nonalcoholic Steatohepatitis via Inhibiting Gut-Derived Endotoxin Mediated TLR4/NF-κB Activation. | 2017 | Details |
A32284 | 28792647 | Liver Int | Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition. | 2017 | Details |
A32286 | 28792295 | Prehosp Emerg Care | Medical Care at a Large Vertical Running Event. | 2017 | Details |
A32521 | 28214071 | Trends Endocrinol Metab | Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. | 2017 | Details |
A32526 | 28202625 | Cancer Discov | Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity. | 2017 | Details |
A32563 | 28109017 | J Gastroenterol Hepatol | Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. | 2017 | Details |
A32688 | 27761198 | J Radiol Case Rep | Percutaneous Transhepatic Embolization of Bleeding Rectal Varices Using A New Embolic And Sclerotic Mixture Augmented By Amplatzer Vascular Plug 2. | 2016 | Details |
A32721 | 29922669 | Inflamm Intest Dis | Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? | 2016 | Details |
A32733 | 27657051 | Int J Mol Sci | Molecular Pathogenesis of NASH. | 2016 | Details |
A33329 | 26213897 | Nat Mater | A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices. | 2015 | Details |
A34229 | 24021426 | J Hepatol | Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. | 2013 | Details |
A34292 | 23841574 | Chem Biol Drug Des | Tricyclic sesquiterpenes from Vetiveria zizanoides (L.) Nash as antimycobacterial agents. | 2013 | Details |
A34339 | 23707371 | J Hepatol | Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. | 2013 | Details |
A34455 | 23402745 | J Hepatol | Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. | 2013 | Details |
A34574 | 23170161 | Gut Liver | A case of nonalcoholic steatohepatitis and small intestinal bacterial overgrowth with peripheral edema caused by intestinal bypass surgery and relieved by repair. | 2012 | Details |
A34631 | 23029000 | PLoS One | VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. | 2012 | Details |
A34756 | 22690069 | World J Gastroenterol | Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. | 2012 | Details |
A35071 | 21805170 | Dig Dis Sci | Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. | 2011 | Details |
A35113 | 21711424 | Hepatol Res | Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. | 2011 | Details |
A35129 | 21673361 | J Physiol Pharmacol | Gut clock: implication of circadian rhythms in the gastrointestinal tract. | 2011 | Details |